7th Annual Global Drug Discovery to Development Innovation Forum 2014

Transcription

1 13 14 May 2014 Intercontinental Hotel Westminster 28 Broadway, London SW1H, UK 7th Annual Global Drug Discovery to Development Innovation Forum 2014 Leverage Innovation embrace change and empower new mindsets to transform the future of R&D Be a Part of Pharma 2.0 Global Speaker Advisory Board And Programme at a Glance: Advance, progressive R&D innovation The latest in big data solutions Novel therapies in companion diagnostics Identifying new collaboration opportunities The GDDIF leaders summit is the only gathering dedicated to deliver the world's most prominent decision makers and thought leaders across all areas of drug discovery and development. It is a platform for key thinkers and industry leaders to present, network and learn through cutting edge ideas that will examine key challenges and objectives now and in the crucial years to come Up to 150 Invited decision makers in attendance It is predicted that the world pharma clinical trials market will be worth Live Innovation Demo's & Workshops over $32 billion in Are you ready to step up? Limited Exhibitor Capacity & Gala Dinner End User Focus & Multiple Themed Round Tables 20 min Innovation spotlight sessions 2 hours dedicated to vendor presentations Tina Flatau VP Alliances & Projects Prosensa Therapeutics BV Theo Meert Head Neurosciences Janssen Pharmaceuticals of J&J Mark Holbrook, VP Lead Global Safety Pharmacology & Site Lead Safety Covance Laboratories Ulrich Betz, Director Head Innovation & Entrepreneurship Incubator Merck Serono Leading Platinum Partners at a Glance: Sold Out 2014!

2 Access to Invited decision makers only Live Innovation Demo's & Workshops Limited Exhibitor Capacity & Gala Dinner End User Programme Focus Join up to 150 Invited decision makers Up to 40 presentations Pre qualified one to one meetings Bespoke Themed Roundtables 7th Drug Discovery Series Will Highlight: Preliminary Attendee Delegate List Automation of workflow Empowering, Adapting & Actioning Innovation Biomarkers To Translate, Predict and action Oncology Biomarkers from Proof of Principle to Proof-of-Concept and Beyond Biomarkers in Discovery and in Clinical Trials "Increasing Value with Personalized Healthcare" Discovery of Pharmacogenomics Biomarkers Cardiovascular and CNS Disorders through Expression Genomics The acceleration of the drug discovery process Innovation across all areas of the preclinical timeline Cutting Edge IT solutions The future of personalised medicine Integration of processes Senior VP Discovery Portfolio & Translational Science Senior Director Pharmacology Vice President Research Policy & Collaborations Global Head Strategic Alliances Managing Director Executive Director, Biomarkers Head of Oncology Bioinformatics Director Preclinical Development Scientific Director Head of Biomarker Development Director Analytical R&D Head of Structure, Design & Informatics Head of Computer Aided Drug Discovery Head of Immunoscience Chemistry Director Developmental & Molecular Pathways Director of Cheminformatics Director IT Research Director Discovery Chemistry

3 Agenda at a Glance - Day 1 (13/05/2014) 9.00 Where is the innovators playground? Mark Holbrook, VP, lead global safety pharmacology and site lead safety assessment, Covance Laboratories 9.30 Open source software and collaboration in drug discovery Kees von Bochove, CEO, The Hyve New approaches to foster innovation and entrepreneurship in drug discovery Ulrich Betz, Director, Head Innovation & Entrepreneurship Incubator, Merck Serono The Importance of Physical Properties in Decreasing Drug Attrition David Elder, Director, SCINOVO, GlaxoSmithKline Morning Refreshments & Networking 11:30 How to assess the quality of your data sets - Title to be updated Ashley George, Global Head of IT Lite, GlaxoSmithKline 12:00 Learning from Historical Data: Data Mining Meets Molecular Design Jan Kriegl, Director, Computational Chemistry Boehringer Ingelheim 12:30 Predictive models and rational design for antisense drug discovery Morten Lindow, Associate Director, Informatics Santaris Pharma 13:00 Networking Lunch The Roche Platform for Non-Clinical Safety Data Integration & Exchange Alessandro Brigo, Principal Scientist, Pharma Research & Early Development - Pharmaceutical Sciences, F. Hoffmann-La Roche 14:.30 Fostering, Applying, and Re-Applying Inteligience from the Analytical Lab Ryan Sasaki, Director of Global Strategy, ACD/Labs Afternoon Coffee Break Innovation in medicinal chemistry: what are the new technologies? Stevan W Djuric, Sr Director, Abbvie Leaders Panel: Discussing innovation past and present Accessing external R&D Innovation Panel members: Mark Holbrook, Covance Laboratories - Chairperson Theo Meert, Johnson & Johnson Tina Flatau, Prosensa Therapeutics BV

4 Draft Agenda at a Glance - Day 2 (14/05/2014) 9.00 Rare, Lean and Determined bringing forward new technologies for orphan disease Tina Flatau, VP Alliances and Projects, Prosensa Therapeutics BV 9.30 External Innovation at Pierre Fabre Alexander Scheer, Deputy Head of Research, Pierre Fabre Antibodies as tools in NCE discovery Alistair Lawson, Head of Antibody Biology, UCB Virtual vs Internal Research Theo Meert, Head Neurosciences, Janssen Pharmaceuticals of J&J :45 Morning Refreshments & Networking New paradigms in GPCR drug discovery Stephan Schann, Head of Research, Domain Therapeutics 12:15 Natural Products Chemistry in Drug Discovery and Development Armin Bauer, Associate Director of Medicinal Chemistry, Sanofi-Aventis 12:45 Networking Lunch 13: A system for fast determination of growth and motility of cells in vitro and its application for testing chemotherapeutic agents Daniel Zicha, Head of Light Microscopy Cancer Research UK, London Research Institute Using Bioactivity Databases, Gene Expression Data and Computational Algorithms: From Ligand Design to Mode-of-Action Analysis Andreas Bender, Lecturer for Molecular Informatics University of Cambridge Capacity building & funding possibilities for academic drug discovery research in Flanders Belgium Jurgen Joossens, Champion Serine Protease Platform, University of Antwerp 15:15 External Sources of Innovation in the Pharmaceutical Industry Andreas Kandelbauer, School of Applied Chemistry, Reutlingen University (co-authored by Alexander Schuhmacher, Professor, School of Applied Chemistry Reutlingen University 15:45 The dark side of Stem Cells Prof Agamemnon A Epenetos, Ph D, FRCP, Chairman and CEO, Trojantec Ltd

5 22nd-23rd Oct 2014 Boston USA 22nd-23rd Oct 2014 Boston USA 10th-11thJun 2014 Boston USA Revere Hotel Similar Forth Coming 2014 Summits Register Now: Telephone: +44 (0) Online: Team discounts of up to 20% available Key Contacts Herbert Ryan Manager, Life Sciences At GBX Summits, our goal is to provide a place to benchmark, network, and exchange cutting edge ideas. Through executive meetings and highly interactive conferences, we enable key decision makers within the pharmaceutical industry to address and define their key challenges and objectives, now and in the crucial years to come. Maya Lee Delegate Acquisition Executive Luisa Kahmann Operations Manager Johan Synclair Sponsorship Manager